Skip to main content
. 2020 May 14;13:4169–4181. doi: 10.2147/OTT.S245091

Figure 4.

Figure 4

LncRNA-UCA1 knockdown facilitates the anticancer effects of metformin against colon cancer cells in vitro. (A) qRT-PCR was conducted to evaluate the effects of MET or UCA1 knockdown or MET + UCA1 knockdown on the expression of lncRNA-UCA1 in the SW480 and SW620 cells in vitro. (B) CCK-8 cellular viability assays were used to test the antiproliferative effects of MET or UCA1 knockdown or MET + UCA1 knockdown on colon cancer cells in vitro. (C) A flow cytometry-based method was conducted to test the effects of MET or UCA1 knockdown or MET + UCA1 knockdown on the cellular apoptosis of the SW480 and SW620 cells in vitro. (D) Western blotting was conducted to evaluate the effects of MET or UCA1 knockdown or MET + UCA1 knockdown on the expression of two proliferation-related markers (p21 and PCNA) and three apoptosis-related markers (Bax, Bcl-2 and cleaved caspase3) in colon cancer cells. *p-value<0.05; **p-value<0.01; ***p-value<0.001. One-way ANOVA is used in AC.